We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Dalton Pharma Services has launched the good manufacturing practice (GMP) campaign for Arch Biopartners’ AB569, an inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs.